221 related articles for article (PubMed ID: 27872058)
21. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
Fathi AT; Chen YB
Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
[TBL] [Abstract][Full Text] [Related]
22. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Wei AH; Tiong IS
Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
[TBL] [Abstract][Full Text] [Related]
23. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Sahoo RK; Kumar L
N Engl J Med; 2017 Nov; 377(19):1901-2. PubMed ID: 29120133
[No Abstract] [Full Text] [Related]
24. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Stone RM; Larson RA; Döhner H
N Engl J Med; 2017 Nov; 377(19):1903. PubMed ID: 29117486
[No Abstract] [Full Text] [Related]
25. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.
Smith CC; Paguirigan A; Jeschke GR; Lin KC; Massi E; Tarver T; Chin CS; Asthana S; Olshen A; Travers KJ; Wang S; Levis MJ; Perl AE; Radich JP; Shah NP
Blood; 2017 Jul; 130(1):48-58. PubMed ID: 28490572
[TBL] [Abstract][Full Text] [Related]
26. Midostaurin approved for FLT3-mutated AML.
Levis M
Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Webster JA; Tibes R; Morris L; Blackford AL; Litzow M; Patnaik M; Rosner GL; Gojo I; Kinders R; Wang L; Doyle LA; Huntoon CJ; Karnitz LM; Kaufmann SH; Karp JE; Smith BD
Leuk Res; 2017 Oct; 61():108-116. PubMed ID: 28957699
[TBL] [Abstract][Full Text] [Related]
28. Clinical use of FLT3 inhibitors in acute myeloid leukemia.
Sutamtewagul G; Vigil CE
Onco Targets Ther; 2018; 11():7041-7052. PubMed ID: 30410361
[TBL] [Abstract][Full Text] [Related]
29. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
30. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
31. A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.
Kantarjian HM; Schuster MW; Jain N; Advani A; Jabbour E; Gamelin E; Rasmussen E; Juan G; Anderson A; Chow VF; Friberg G; Vogl FD; Sekeres MA
Am J Hematol; 2017 Jul; 92(7):660-667. PubMed ID: 28370201
[TBL] [Abstract][Full Text] [Related]
32. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of acute promyelocytic leukemia treated with all-
Abaza Y; Kantarjian H; Garcia-Manero G; Estey E; Borthakur G; Jabbour E; Faderl S; O'Brien S; Wierda W; Pierce S; Brandt M; McCue D; Luthra R; Patel K; Kornblau S; Kadia T; Daver N; DiNardo C; Jain N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Estrov Z; Foudray M; McCue D; Cortes J; Ravandi F
Blood; 2017 Mar; 129(10):1275-1283. PubMed ID: 28003274
[TBL] [Abstract][Full Text] [Related]
34. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
Park H; Chung H; Lee J; Jang J; Kim Y; Kim SJ; Kim JS; Min YH; Cheong JW
Yonsei Med J; 2017 Jan; 58(1):35-42. PubMed ID: 27873493
[TBL] [Abstract][Full Text] [Related]
35. Gilteritinib or Chemotherapy for Relapsed or Refractory
Perl AE; Martinelli G; Cortes JE; Neubauer A; Berman E; Paolini S; Montesinos P; Baer MR; Larson RA; Ustun C; Fabbiano F; Erba HP; Di Stasi A; Stuart R; Olin R; Kasner M; Ciceri F; Chou WC; Podoltsev N; Recher C; Yokoyama H; Hosono N; Yoon SS; Lee JH; Pardee T; Fathi AT; Liu C; Hasabou N; Liu X; Bahceci E; Levis MJ
N Engl J Med; 2019 Oct; 381(18):1728-1740. PubMed ID: 31665578
[TBL] [Abstract][Full Text] [Related]
36. Molecular synergy underlies the co-occurrence patterns and phenotype of
Dovey OM; Cooper JL; Mupo A; Grove CS; Lynn C; Conte N; Andrews RM; Pacharne S; Tzelepis K; Vijayabaskar MS; Green P; Rad R; Arends M; Wright P; Yusa K; Bradley A; Varela I; Vassiliou GS
Blood; 2017 Oct; 130(17):1911-1922. PubMed ID: 28835438
[No Abstract] [Full Text] [Related]
37. AML in 2016: Where we are now?
Rowe JM
Best Pract Res Clin Haematol; 2016 Dec; 29(4):315-319. PubMed ID: 27890252
[TBL] [Abstract][Full Text] [Related]
38. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
39. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
Larrosa-Garcia M; Baer MR
Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Löwenberg B; Pabst T; Maertens J; van Norden Y; Biemond BJ; Schouten HC; Spertini O; Vellenga E; Graux C; Havelange V; de Greef GE; de Weerdt O; Legdeur MJ; Kuball J; Kooy MV; Gjertsen BT; Jongen-Lavrencic M; van de Loosdrecht AA; van Lammeren-Venema D; Hodossy B; Breems DA; Chalandon Y; Passweg J; Valk PJ; Manz MG; Ossenkoppele GJ;
Blood; 2017 Mar; 129(12):1636-1645. PubMed ID: 28049642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
